Literature DB >> 1378015

Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.

H Wang1, S Müller, S Zolla-Pazner, H Köhler.   

Abstract

Human monoclonal and purified polyclonal anti-human immunodeficiency virus (HIV)-1 antibodies were tested for binding to a murine monoclonal anti-idiotypic antibody (1F7, IgM, kappa). Four human monoclonal anti-p24 and three human monoclonal anti-gp120 antibodies express the 1F7 clonotype, while one human monoclonal anti-gp41 antibody does not bind to 1F7. Affinity-purified anti-p24 and anti-gp120 antibodies from HIV-1-infected individuals also react with 1F7. Western blot analysis and enzyme-linked immunosorbent assay confirmed that 1F7 reacts with human antibodies of different HIV-1 antigen specificities. A survey of sera from 329 HIV-1-infected individuals showed binding to 1F7 in 239 sera (72.6%) while 1F7 was not reacting with 109 HIV-1-negative sera. These results show that 1F7 idiotype is an HIV-1 infection-associated clonotypic marker shared by anti-HIV-1 antibodies with different epitope specificites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378015     DOI: 10.1002/eji.1830220713

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire.

Authors:  Matthew S Parsons; Robert J Center; Jean-Pierre Routy; Danielle Rouleau; Roger Leblanc; Mark A Wainberg; Cécile L Tremblay; Marcel D Zannou; Stephen J Kent; Michael D Grant; Nicole F Bernard
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01-29       Impact factor: 2.205

2.  Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory Fc receptor interactions that reduce target cell availability.

Authors:  Anthony J Smith; Stephen W Wietgrefe; Liang Shang; Cavan S Reilly; Peter J Southern; Katherine E Perkey; Lijie Duan; Heinz Kohler; Sybille Müller; James Robinson; John V Carlis; Qingsheng Li; R Paul Johnson; Ashley T Haase
Journal:  J Immunol       Date:  2014-08-20       Impact factor: 5.422

3.  Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.

Authors:  S Müller; D H Margolin; P L Nara; W G Alvord; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

4.  Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.

Authors:  K Hariharan; P L Nara; V M Caralli; F L Norton; N Haigwood; C Y Kang
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

5.  Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency virus-1-infected individuals.

Authors:  Q L Wang; H T Wang; E Blalock; S Müller; H Köhler
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 6.  The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus.

Authors:  Sybille Muller; Matthew S Parsons; Heinz Kohler; Michael Grant
Journal:  Front Oncol       Date:  2016-02-05       Impact factor: 6.244

Review 7.  The Promise of Anti-idiotype Revisited.

Authors:  Heinz Kohler; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

8.  The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance.

Authors:  Tigran K Davtyan; David A Poghosyan; Anna G Sukiasyan; Michael D Grant
Journal:  J Inflamm (Lond)       Date:  2013-04-05       Impact factor: 4.981

Review 9.  Multiantibody strategies for HIV.

Authors:  Andrew Hiatt; Larry Zeitlin; Kevin J Whaley
Journal:  Clin Dev Immunol       Date:  2013-06-06

Review 10.  The Homophilic Domain - An Immunological Archetype.

Authors:  Heinz Kohler; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  Front Immunol       Date:  2016-03-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.